Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Antipsychotic Drugs Linked to Decreased Brain Volume

July 21, 2014 3:18 pm | News | Comments

A new study has confirmed a link between antipsychotic medication and a slight, but measureable, decrease in brain volume in patients with schizophrenia. Read more...                        

TOPICS:

Gold Nanoparticles Penetrate Cells, Show Promise for Drug Delivery

July 21, 2014 3:09 pm | Videos | Comments

A special class of tiny gold particles can easily slip through cell membranes, making them good candidates to deliver drugs directly to target cells. Read more...                          

TOPICS:

MetaMax Enrolls First Patients in Trial of Anticancer Drug

July 21, 2014 11:58 am | News | Comments

The first patients have been enrolled in a Phase 1/2a clinical trial of a promising approach to treat malignant neoplasms. Following approval by the Russian Ministry of Health, Russian biotechnology company MetaMax will begin the trial of its lead anticancer compound MM-D37K. Read more...

TOPICS:
Advertisement

First Patients Enrolled in Trial of Opioid Dependence Treatment

July 21, 2014 11:49 am | News | Comments

Braeburn Pharmaceuticals announced that the first patients have been enrolled in its Phase 3 clinical study of Probuphine, a subdermal implant for the maintenance treatment of opioid dependence, for which there is an acute need for innovative and effective treatment options. Read more...

TOPICS:

Combo Therapy Cures Hep C in Co-Infected HIV Patients

July 21, 2014 11:37 am | News | Comments

A multicenter team of researchers report that in a Phase 3 clinical trial, a combination drug therapy — sofosbuvir and ribavirin — cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C. Read more...

TOPICS:

China’s FDA Approves Conduct of Breast Cancer Trial

July 21, 2014 11:31 am | News | Comments

CASI Pharmaceuticals Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced that China's Food and Drug Administration has approved the company's application to conduct a Phase 2 clinical trial in triple-negative breast cancer patients in China for its proprietary drug candidate, ENMD-2076. Read more...

TOPICS:

Researchers Aim to Help Doctors Attack Metastases

July 21, 2014 11:22 am | News | Comments

Researchers at the University of Arkansas have been awarded $1.5 million from the National Cancer Institute at the National Institutes of Health to develop new molecules and biopharmaceuticals that enhance a patient’s immune response against tumors. Read more...

TOPICS:

Allergan to Cut 1,500 Employees in Restructuring

July 21, 2014 11:10 am | by Tom Murphy, AP Business Writer | News | Comments

Botox maker Allergan will cut about 13% of its workforce, or roughly 1,500 employees, as part of a push to become more efficient and productive, and in the takeover battle's latest twist, Valeant said Monday it has complained to regulators that Allergan has been making false statements about its business. Read more...

TOPICS:
Advertisement

JDRF, ViaCyte File IND App for Diabetes Treatment Trial

July 18, 2014 3:30 pm | News | Comments

JDRF announced that ViaCyte Inc. has filed an Investigational New Drug application (IND) with the FDA seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes. Read more...                

TOPICS:

InterMune Gets Breakthrough Therapy Status for IPF Drug

July 18, 2014 3:24 pm | News | Comments

InterMune, Inc. announced that pirfenidone, an investigational treatment for adult patients with idiopathic pulmonary fibrosis (IPF), has been granted Breakthrough Therapy Designation from the FDA. Read more...           

TOPICS:

Amgen's Hyperparathyroidism Drug Hits All Endpoints in Phase 3

July 18, 2014 3:16 pm | News | Comments

Amgen announced that a Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. Read more...   

TOPICS:

Bayer Eye Drug Shows Sustained Vision Improvement in DME

July 18, 2014 3:08 pm | News | Comments

Bayer HealthCare announced that in the Phase 3 VIVID-DME trial of aflibercept solution for injection into the eye for the treatment of vision impairment due to diabetic macular edema (DME), the solution showed a sustained improvement from baseline in best corrected visual acuity (BCVA). Read more...

TOPICS:

Researchers ID Possible Target for Early-Stage Breast Cancer Immunotherapy

July 18, 2014 2:59 pm | News | Comments

Researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. Read more...                         

TOPICS:

Breakthrough May Benefit Bowel Cancer Treatments

July 18, 2014 2:50 pm | News | Comments

Researchers have made a significant breakthrough that may benefit patients with bowel cancer: how two genes cause bowel cancer cells to become resistant to treatments used against the disease. Read more...          

TOPICS:

Prana Updates Alzheimer's Development Program

July 18, 2014 11:38 am | News | Comments

Prana Biotechnology updated its clinical development program for Alzheimer's disease, noting that the starting amyloid burden level (baseline) in the PBT2 treated participant group had an important bearing on the decrease of amyloid over time in that participant (p=0.035), whereas there was no such correlation in the placebo group.. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading